Systemic and ocular absorption and antagonist activity of topically applied cyclopentolate in man

Pharmacology and Toxicology

Volumn 82, Issue 1, 1998, Pages 19-22

  Haaga, Marko ^a   Kaila, T ^b   Salminen, L ^a   Ylitalo, Pauli ^a  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPENTOLATE; MUSCARINIC RECEPTOR BLOCKING AGENT;

ACCOMMODATION; AGED; ANIMAL TISSUE; AQUEOUS HUMOR; ARTICLE; CATARACT; CHOLINERGIC RECEPTOR BLOCKING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG DISTRIBUTION; EXTRACAPSULAR CATARACT EXTRACTION; FEMALE; HEART RATE; HUMAN; MALE; MYDRIASIS; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR OCCUPANCY; TOPICAL DRUG ADMINISTRATION;

ANIMALIA;

EID: 0031912036     PISSN: 09019928     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0773.1998.tb01392.x     Document Type: Article

References (14)

1. Adcock, E. W. III: Cyclopentolate (Cyclogyl) toxicity in pediatric patients. J. Pediatr. 1971, 79, 127-129.
2. Awan, K. J.: Systemic toxicity of cyclopentolate hydrochloride in adults following topical ocular instillation. Ann. Ophtalmol. 1976, 8, 695-698.
3. Ensinger, H. A., D. Wahl & V. Brantl: Radioreceptor assay for the determination of the antimuscarinic drug ipratropium bromide in man. Eur. J. Clin. Pharmacol. 1987, 33, 459-462.
4. Kaila, T., R. Huupponen, L. Salminen & E. Iisalo: Systemic absorption of ophtalmic cyclopentolate. Amer. J. Ophthalmol. 1989, 107, 562-564.
5. Khurana, A. K., B. K. Ahluwalia, C. Rajan & A. K. Vohra: Acute psychosis associated with topical cyclopentolate hydrochloride. Amer. J. Ophthalmol. 1988, 105, 91.
6. Lahdes, K., R. Huupponen, T. Kaila, T. Ali-Melkkilä, L. Salminen & M Saari: Systemic absorption of ocular cyclopentolate in children. German J. Ophthalmol. 1992, 1, 16-18.
7. Lahdes, K., R. Huupponen, T. Kaila, D. Monti, F. Saettone & L. Salminen: Plasma concentrations and ocular effects of cyclopentolate after ocular application of three formulations. Brit. J. Clin. Pharmacol. 1993, 35, 479-483.
8. Lahdes, K.: Systemic absorption and effects of topically applied ocular anticholinergic drugs. Annales Universitatis Turkuensis, 1996, Turku, Finland.
9. Sato, E. H., D. de Freitas & C. S. Foster: Abuse of cyclopentolate hydrochloride (Cyclogyl) drops. New Eng. J. Med. 1992, 326, 1363-1364.
10. Shihab, Z. M.: Psychotic reaction in an adult after topical cyclopentolate. Ophthalmologica 1980, 181, 228-230.
11. Urtti, A. & L. Salminen: Minimizing systemic absorption of topically administered ophthalmic drugs. Surv. Ophthalmol. 1993, 37, 435-456.
12. Wellstein, A. & H. F. Pitschner: Complex dose response curves of atropine in man explained by different functions of M1- and M2-cholinoceptors. Naunyn-Schmeidebergs Arch. Pharmacol. 1988, 338, 19-27.
13. Vuori, M. L., T. Kaila, E. Iisalo & K. M. Saari: Systemic absorption and anticholinergic activity of topically applied tropicamide. J. Ocul. Pharmacol. 1994, 10, 431-437.
14. Zimmerman, T. J., K. S. Kooner, A. S. Kandarakis & L. P. Ziegler: Improving the therapeutic index of topically applied ocular drugs. Arch. Ophthalmol. 1994, 102, 551-553.